Movement Alert｜Argenx SE Rises 4.08% in Regular Trading, Buoyed by Vyvgart Momentum and Analyst Confidence in Q2 Rebound

Market Focus06-05

On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.

The rise comes amid sustained bullish sentiment surrounding Argenx's core product Vyvgart. RBC Capital Markets recently noted that the company appears confident of a Q2 rebound, citing robust Vyvgart momentum driven by high demand and record new patient starts in Q1. Analysts highlighted that Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing, though formulary access could take up to six months. Additionally, RBC identified the upcoming myositis data readout on track for Q3 as the biggest potential catalyst for the stock.

Vyvgart sales have demonstrated exceptional market penetration, growing from $329 million in 2022 to $2.186 billion in 2024. Bernstein has projected Vyvgart could become the fourth-largest autoimmune drug in history. On May 7, Argenx reported Q1 EPS of $5.52, reinforcing its position as one of the fastest biotech companies to reach profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185702184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185702184","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 4.08% in Regular Trading, Buoyed by Vyvgart Momentum and Analyst Confidence in Q2 Rebound","media":"Market Focus","content":"<p><p>On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.</p><p>The rise comes amid sustained bullish sentiment surrounding Argenx's core product Vyvgart. RBC Capital Markets recently noted that the company appears confident of a Q2 rebound, citing robust Vyvgart momentum driven by high demand and record new patient starts in Q1. Analysts highlighted that Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing, though formulary access could take up to six months. Additionally, RBC identified the upcoming myositis data readout on track for Q3 as the biggest potential catalyst for the stock.</p><p>Vyvgart sales have demonstrated exceptional market penetration, growing from $329 million in 2022 to $2.186 billion in 2024. Bernstein has projected Vyvgart could become the fourth-largest autoimmune drug in history. On May 7, Argenx reported Q1 EPS of $5.52, reinforcing its position as one of the fastest biotech companies to reach profitability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 4.08% in Regular Trading, Buoyed by Vyvgart Momentum and Analyst Confidence in Q2 Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 4.08% in Regular Trading, Buoyed by Vyvgart Momentum and Analyst Confidence in Q2 Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.</p><p>The rise comes amid sustained bullish sentiment surrounding Argenx's core product Vyvgart. RBC Capital Markets recently noted that the company appears confident of a Q2 rebound, citing robust Vyvgart momentum driven by high demand and record new patient starts in Q1. Analysts highlighted that Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing, though formulary access could take up to six months. Additionally, RBC identified the upcoming myositis data readout on track for Q3 as the biggest potential catalyst for the stock.</p><p>Vyvgart sales have demonstrated exceptional market penetration, growing from $329 million in 2022 to $2.186 billion in 2024. Bernstein has projected Vyvgart could become the fourth-largest autoimmune drug in history. On May 7, Argenx reported Q1 EPS of $5.52, reinforcing its position as one of the fastest biotech companies to reach profitability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1185702184","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185702184","pubTimestamp":1780589750,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.The rise comes amid sustained bullish sentiment surrounding Argenx's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势警报|Argenx SE在常规交易中上涨4.08%，受Vyvgart势头和分析师对Q2反弹的信心提振","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.The rise comes amid sustained bullish sentiment surrounding Argenx's core product Vyvgart. RBC Capital Markets recently noted that the company appears confident of a Q2 rebound, citing robust Vyvgart momentum driven by high demand and record new patient starts in Q1. Analysts highlighted that Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing, though formulary access could take up to six months. Additionally, RBC identified the upcoming myositis data readout on track for Q3 as the biggest potential catalyst for the stock.Vyvgart sales have demonstrated exceptional market penetration, growing from $329 million in 2022 to $2.186 billion in 2024. Bernstein has projected Vyvgart could become the fourth-largest autoimmune drug in history. On May 7, Argenx reported Q1 EPS of $5.52, reinforcing its position as one of the fastest biotech companies to reach profitability.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185702184","isCrawlerRequest":true}